Tuesday, February 7, 2023
Google search engine
HomeMarketResultsMiMedx Group, Inc. (NASDAQ:MDXG) CFO Sells $14,077.44 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CFO Sells $14,077.44 in Stock


MiMedx Group, Inc. (NASDAQ:MDXGGet Rating) CFO Peter M. Carlson offered 4,992 shares of the inventory in a transaction dated Thursday, December twenty second. The inventory was offered at a median worth of $2.82, for a complete transaction of $14,077.44. Following the transaction, the chief monetary officer now owns 565,206 shares of the corporate’s inventory, valued at $1,593,880.92. The transaction was disclosed in a submitting with the SEC, which is on the market by this hyperlink.

MiMedx Group Inventory Down 1.8 %

Shares of MDXG traded down $0.05 throughout buying and selling hours on Tuesday, hitting $2.72. The corporate had a buying and selling quantity of 549,282 shares, in comparison with its common quantity of 529,846. The enterprise has a fifty day shifting common of $3.02 and a 200-day shifting common of $3.31. The agency has a market cap of $309.18 million, a price-to-earnings ratio of -9.07 and a beta of 1.76. MiMedx Group, Inc. has a 12 month low of $2.43 and a 12 month excessive of $6.40.

MiMedx Group (NASDAQ:MDXGGet Rating) final introduced its quarterly earnings outcomes on Wednesday, November 2nd. The corporate reported ($0.09) EPS for the quarter, assembly analysts’ consensus estimates of ($0.09). The corporate had income of $67.69 million in the course of the quarter, in comparison with analyst estimates of $65.37 million. On common, equities analysts count on that MiMedx Group, Inc. will publish -0.29 EPS for the present fiscal 12 months.

Wall Road Analysts Forecast Progress

MDXG has been the subject of quite a few analyst reviews. StockNews.com upgraded MiMedx Group from a “maintain” ranking to a “purchase” ranking in a analysis observe on Thursday, October twentieth. Mizuho initiated protection on shares of MiMedx Group in a analysis observe on Wednesday, October twelfth. They set a “purchase” ranking and a $7.00 worth goal on the inventory. Lastly, HC Wainwright diminished their worth goal on MiMedx Group from $8.50 to $8.00 and set a “purchase” ranking for the corporate in a report on Wednesday, September seventh.

Hedge Funds Weigh In On MiMedx Group

Massive traders have not too long ago made adjustments to their positions within the firm. Swiss Nationwide Financial institution grew its holdings in MiMedx Group by 8.2% within the 1st quarter. Swiss Nationwide Financial institution now owns 172,400 shares of the corporate’s inventory valued at $812,000 after shopping for a further 13,000 shares within the final quarter. JPMorgan Chase & Co. boosted its place in shares of MiMedx Group by 16.7% within the first quarter. JPMorgan Chase & Co. now owns 78,218 shares of the corporate’s inventory valued at $368,000 after buying a further 11,208 shares in the course of the interval. E Fund Administration Co. Ltd. acquired a brand new place in shares of MiMedx Group within the first quarter valued at about $50,000. Acadian Asset Administration LLC purchased a brand new place in MiMedx Group in the course of the first quarter price about $151,000. Lastly, MetLife Funding Administration LLC raised its stake in MiMedx Group by 56.2% within the 1st quarter. MetLife Funding Administration LLC now owns 62,811 shares of the corporate’s inventory price $296,000 after buying a further 22,593 shares within the final quarter. Institutional traders personal 56.56% of the corporate’s inventory.

About MiMedx Group

(Get Rating)

MiMedx Group, Inc develops and distributes placental tissue allografts for numerous sectors of healthcare. It processes the human placental tissues using its patented and proprietary PURION course of to provide allografts that retains the tissue’s inherent organic properties and regulatory proteins.

See Additionally

Insider Buying and Selling by Quarter for MiMedx Group (NASDAQ:MDXG)

This immediate information alert was generated by narrative science know-how and monetary knowledge from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account MiMedx Group, you may need to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and MiMedx Group wasn’t on the record.

Whereas MiMedx Group at present has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments